71 related articles for article (PubMed ID: 16447243)
1. Platelet C4d is highly specific for systemic lupus erythematosus.
Navratil JS; Manzi S; Kao AH; Krishnaswami S; Liu CC; Ruffing MJ; Shaw PS; Nilson AC; Dryden ER; Johnson JJ; Ahearn JM
Arthritis Rheum; 2006 Feb; 54(2):670-4. PubMed ID: 16447243
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
[TBL] [Abstract][Full Text] [Related]
3. Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.
Qin S; Wang X; Wang J; Wu H
Lupus; 2024 Feb; 33(2):111-120. PubMed ID: 38227433
[No Abstract] [Full Text] [Related]
4. Platelet LGALS3BP as a Mediator of Myeloid Inflammation in Systemic Lupus Erythematosus.
El Bannoudi H; Cornwell M; Luttrell-Williams E; Engel A; Rolling C; Barrett TJ; Izmirly P; Belmont HM; Ruggles K; Clancy R; Buyon J; Berger JS
Arthritis Rheumatol; 2023 May; 75(5):711-722. PubMed ID: 36245285
[TBL] [Abstract][Full Text] [Related]
5. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
Wallace DJ; Silverman SL; Conklin J; Barken D; Dervieux T
Lupus Sci Med; 2016; 3(1):e000127. PubMed ID: 26870391
[TBL] [Abstract][Full Text] [Related]
6. Deciphering Abnormal Platelet Subpopulations in COVID-19, Sepsis and Systemic Lupus Erythematosus through Machine Learning and Single-Cell Transcriptomics.
Qiu X; Nair MG; Jaroszewski L; Godzik A
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892129
[TBL] [Abstract][Full Text] [Related]
7. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
8. Stroke as an unusual initial presentation of 'malignant' middle cerebral artery infarction involvement in systemic lupus erythematosus.
Habes YMN; Ahmaro M; Dwikat Y; Jobran AWM; Abunejma FM; Abdulrazzak M
Ann Med Surg (Lond); 2024 Jan; 86(1):517-521. PubMed ID: 38222771
[TBL] [Abstract][Full Text] [Related]
9. Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management.
Cole MA; Gerber GF; Chaturvedi S
Clin Immunol; 2023 Dec; 257():109828. PubMed ID: 37913840
[TBL] [Abstract][Full Text] [Related]
10. Complement as a Biomarker for Systemic Lupus Erythematosus.
Ayano M; Horiuchi T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830735
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus.
Oliveira CB; Kaplan MJ
Semin Immunopathol; 2022 May; 44(3):309-324. PubMed ID: 35355124
[TBL] [Abstract][Full Text] [Related]
12. Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus.
Gartshteyn Y; Mor A; Shimbo D; Khalili L; Kapoor T; Geraldino-Pardilla L; Alexander RV; Conklin J; Dervieux T; Askanase AD
Clin Immunol; 2021 Jul; 228():108755. PubMed ID: 33984497
[TBL] [Abstract][Full Text] [Related]
13. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.
Svenungsson E; Gustafsson JT; Grosso G; Rossides M; Gunnarsson I; Jensen-Urstad K; Larsson A; Ekdahl KN; Nilsson B; Bengtsson AA; Lood C
Rheumatology (Oxford); 2020 Nov; 59(11):3264-3274. PubMed ID: 32259250
[TBL] [Abstract][Full Text] [Related]
14. Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome.
Petri M
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):415-420. PubMed ID: 31808834
[TBL] [Abstract][Full Text] [Related]
15. Potential Roles of Antiphospholipid Antibodies in Generating Platelet-C4d in Systemic Lupus Erythematosus.
Liu CC; Schofield T; Tang A; Manzi S; Ahearn JM
Antibodies (Basel); 2017 Jul; 6(3):. PubMed ID: 31548524
[TBL] [Abstract][Full Text] [Related]
16. Platelets in Skin Autoimmune Diseases.
Liu X; Gorzelanny C; Schneider SW
Front Immunol; 2019; 10():1453. PubMed ID: 31333641
[TBL] [Abstract][Full Text] [Related]
17. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE.
Petri MA; Conklin J; O'Malley T; Dervieux T
Lupus Sci Med; 2019; 6(1):e000318. PubMed ID: 31168401
[TBL] [Abstract][Full Text] [Related]
18. Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in Murine Lupus Nephritis.
Gonzalo-Gil E; García-Herrero C; Toldos O; Usategui A; Criado G; Pérez-Yagüe S; Barber DF; Pablos JL; Galindo M
Front Immunol; 2018; 9():1948. PubMed ID: 30210500
[No Abstract] [Full Text] [Related]
19. The non-haemostatic role of platelets in systemic lupus erythematosus.
Linge P; Fortin PR; Lood C; Bengtsson AA; Boilard E
Nat Rev Rheumatol; 2018 Mar; 14(4):195-213. PubMed ID: 29559714
[TBL] [Abstract][Full Text] [Related]
20. Cell-bound complement activation products in SLE.
Ramsey-Goldman R; Li J; Dervieux T; Alexander RV
Lupus Sci Med; 2017; 4(1):e000236. PubMed ID: 29214038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
